Altoida, Inc is making brain health smart and personal. The company’s approach combines novel digital biomarkers (dBM) with immersive augmented reality (AR) and powerful artificial intelligence (AI).
Altoida’s precision neurology device planned for use in Alzheimer’s disease and dementia diagnosis has been awarded Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).
Related Reading:
- Biogen launching new study to develop digital biomarkers using Apple Watch and iPhone
- Digital biomarker for Diabetes can now be identified using your SmartPhone and a little AI
- Careband, Tile and Amazon join forces to support people living with dementia
- Your smartphone can detect early onset of Alzheimer’s disease as you type
The non-invasive software device which measures and monitors neurocognitive function is now being evaluated to predict conversion from Mild Cognitive Impairment to Alzheimer’s disease with artificial intelligence.
Altoida’s device collects personalized brain data by asking users to complete a 10 minute set of augmented reality and motor activities on their smartphone or tablet.
From nearly 800 digital biomarkers collected, Altoida measures and monitors 11 unique neurocognitive domains and is working to use artificial intelligence to predict conversion to Alzheimer’s disease before symptomatic onset.
With this data, the device will use artificial intelligence to predict if an individual aged 55+ with Mild Cognitive Impairment will or will not convert to Alzheimer’s disease within 12 months.
“We are proud to receive this designation for the Altoida device, which will be a completely digital solution for predictive Alzheimer’s disease diagnosis,” said Travis Bond, CEO of Altoida. “This significant milestone enables Altoida to pioneer a new generation of precision neurology devices which leverage artificial intelligence for prediction of neurodegenerative disorders before onset, rather than rely on analysis of symptoms after onset. We look forward to working with the FDA to continue development of our device and to make highly accurate, non-invasive, and cost effective diagnosis of neurodegenerative disorders universally accessible, beginning with Alzheimer’s disease.”
Altoida’s device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.
